VERTEX PHARMACEUTICALS INC / MA Cash Flow Hedge Derivative Instrument Liabilities at Fair Value
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Cash Flow Hedge Derivative Instrument Liabilities at Fair Value of $5.60 million as of 2021-12-31, per its 10-K filed 2022-02-09.
Discontinued › Notes › Derivative Instruments and Hedging Activities › Summary of Derivative Instruments
us-gaap:CashFlowHedgeDerivativeInstrumentLiabilitiesAtFairValue · last filed 2022-02-09
- 2021-12-31: Cash Flow Hedge Derivative Instrument Liabilities at Fair Value $5.60M.
- 2020-12-31: Cash Flow Hedge Derivative Instrument Liabilities at Fair Value $59.20M; Cash Flow Hedge Derivative Instrument Liabilities at Fair Value as first filed $59.18M.
- 2019-12-31: Cash Flow Hedge Derivative Instrument Liabilities at Fair Value $5.53M.
| Period end | Cash Flow Hedge Derivative Instrument Liabilities at Fair Value | Cash Flow Hedge Derivative Instrument Liabilities at Fair Value as first filed |
|---|---|---|
| 2021-12-31 | $5.60M 10-K · filed 2022-02-09 | |
| 2020-12-31 | $59.20M 10-K · filed 2022-02-09 | $59.18M 10-K · filed 2021-02-11 |
| 2019-12-31 | $5.53M 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |